Kamala Rajupet, MD
Endocrinology, Diabetes & Metabolism · Natrona Heights, PANPI 1467470229
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,675 of the $42,530 with a category attached, or 72.1%. 37 manufacturers reported payments, led by Lilly USA, LLC at 51.8% of the total. Reporting peaked in 2019 at $23,526 and has fallen 97.8% since, to $512 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $107.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$22K
- Valeritas, Inc.$7K
- Mannkind Corporation$6K
- AstraZeneca$2K
- Zealand Pharma US, Inc.$2K
- Novo Nordisk$983
- plus $2K from 31 others
What the payments were for
- Consulting fees$2,6006%
- Speaking & faculty fees$30,67572%
- Travel & lodging$3,2108%
- Food & beverage$5,84414%
- Education$1410%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 98 | $22,050 |
| Valeritas, Inc. | 26 | $6,881 |
| Mannkind Corporation | 18 | $5,819 |
| AstraZeneca(2 entities) | 30 | $2,315 |
| Zealand Pharma US, Inc. | 3 | $2,020 |
| Novo Nordisk | 75 | $983 |
| Boehringer Ingelheim | 32 | $474 |
| Sanofi-aventis U.S. LLC | 16 | $243 |
| BD | 12 | $232 |
| Merck | 16 | $153 |
| Amgen | 6 | $138 |
| Bayer | 7 | $119 |
| Medtronic(2 entities) | 5 | $108 |
| Ardelyx, Inc. | 5 | $98 |
| Insulet Corporation | 5 | $98 |
| Vifor Pharma, Inc. | 3 | $71 |
| Fresenius USA Marketing, Inc. | 3 | $68 |
| Shire North American Group Inc | 3 | $64 |
| Novartis | 3 | $57 |
| Abbott | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $53 |
| Johnson & Johnson | 3 | $50 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| AbbVie | 3 | $47 |
| Dexcom, Inc. | 2 | $34 |
| Corcept Therapeutics | 2 | $32 |
| Tandem Diabetes Care, Inc. | 2 | $30 |
| BETA Bionics, Inc. | 2 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,530 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 661 | $601,075 |
| OzempicSemaglutide | 384 | $431,548 |
| MounjaroTirzepatide | 286 | $360,804 |
| TrulicityDulaglutide | 204 | $246,689 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $55,950 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 79 | $50,465 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 47 | $50,098 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $46,572 |
| FarxigaDapagliflozin Propanediol | 30 | $45,313 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 266 | $38,021 |
| Novolog FlexpenInsulin Aspart | 131 | $35,416 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 69 | $34,271 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $33,158 |
| Humalog Kwikpen U-100Insulin Lispro | 111 | $32,613 |
| JanuviaSitagliptin Phosphate | 37 | $31,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $22,050 | $622,532576 claims |
| Boehringer IngelheimJardiance, Tradjenta | $474 | $617,445681 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $983 | $454,561461 claims |
| AstraZenecaFarxiga | $2,315 | $45,31330 claims |
| MerckJanuvia | $153 | $31,05737 claims |
| AbbVieSynthroid | $47 | $12,452252 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $11,9291,072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Natrona Heights
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.